Ignite Creation Date:
2025-12-25 @ 4:03 AM
Ignite Modification Date:
2026-02-09 @ 2:58 AM
Study NCT ID:
NCT01234402
Status:
COMPLETED
Last Update Posted:
2019-08-14
First Post:
2010-11-03
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Sponsor:
Eli Lilly and Company
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-03
Start Date Type:
None
Primary Completion Date:
2013-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-07
Completion Date Type:
ACTUAL
First Submit Date:
2010-11-03
First Submit QC Date:
None
Study First Post Date:
2010-11-04
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-06-13
Results First Submit QC Date:
None
Results First Post Date:
2019-08-14
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2014-10-08
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2019-07-21
Last Update Post Date:
2019-08-14
Last Update Post Date Type:
ACTUAL